FDAnews
www.fdanews.com/articles/149540-eli-lilly-pet-drug-misbranded-by-misleading-imagery-fda-says

Eli Lilly PET Drug Misbranded by Misleading Imagery, FDA Says

September 18, 2012
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a webpage advertisement and other promotional materials for the product, according to an FDA untitled letter. The materials misleadingly suggest that Amyvid (florbetapir F 18 injection) PET images can be displayed, and therefore interpreted, in color for patients being evaluated for Alzheimer’s disease and other causes of cognitive decline.
Washington Drug Letter